CAMBRIDGE, Mass., March 25, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in
precision genetic medicine for rare diseases, announced that it will host a webcast and conference call at 8:00 a.m. Eastern Time
(ET) on Monday, March 25, 2019. On the call, Sarepta will provide an update on encouraging 9-month functional and creatine kinase
(CK) data from baseline for the 4 patients in the Phase 1 open-label study of Sarepta’s micro-dystrophin gene therapy candidate for
Duchenne muscular dystrophy (DMD). While Sarepta does not intend to provide continuing updates on the patients in its Phase 1
study while it enrolls and conducts its current 24-patient, double-blind, placebo-controlled trial, Sarepta has been informed that
its principal investigator recently presented data at a scientific meeting, and believes it appropriate to provide broad access to
the data through this webcast and conference call.
The 8:00 a.m. ET conference call may be accessed by dialing (844) 534-7313 for domestic callers and (574)
990-1451 for international callers. The passcode for the call is 9075206. Please specify to the operator that you would like to
join the “Sarepta Update Call.”
The conference call will be webcast live under the investor relations section of Sarepta's website at www.sarepta.com and will be archived there following the call for 90 days. Please connect to
Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be
necessary.
About Sarepta Therapeutics
Sarepta is at the forefront of precision genetic medicine, having built an impressive and competitive position in Duchenne muscular
dystrophy (DMD) and more recently in gene therapies for 5 Limb-girdle muscular dystrophy diseases (LGMD), Charcot-Marie-Tooth
(CMT), MPS IIIA, Pompe and other CNS-related disorders, totaling over 20 therapies in various stages of development. The Company’s
programs and research focus span several therapeutic modalities, including RNA, gene therapy and gene editing. Sarepta is fueled by
an audacious but important mission: to profoundly improve and extend the lives of patients with rare genetic-based diseases. For
more information, please visit www.sarepta.com.
Internet Posting of Information
We routinely post information that may be important to investors in the 'For Investors' section of our
website at www.sarepta.com. We encourage investors and potential investors to
consult our website regularly for important information about us.
Source: Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc.
Investors:
Ian Estepan, 617-274-4052
iestepan@sarepta.com
Media:
Tracy Sorrentino, 617-301-8566
tsorrentino@sarepta.com
